1. SMEDDS for improved oral bioavailability and anti-hyperuricemic activity of licochalcone A.
- Author
-
Zhu, Zhongan, Liu, Jing, Yang, Yuhang, Adu-Frimpong, Michael, Ji, Hao, Toreniyazov, Elmurat, Wang, Qilong, Yu, Jiangnan, and Xu, Ximing
- Subjects
BIOAVAILABILITY ,ZETA potential ,SPRAGUE Dawley rats ,DRUG delivery systems ,ANIMAL disease models ,TRANSMISSION electron microscopy ,URIC acid - Abstract
The aim of this study was to develop licochalcone A-loaded self-microemulsifying drug delivery system (LCA-SMEDDS) to improve bioavailability and anti-hyperuricemic activity of hydrophobic natural compound licochalcone A (LCA). The prepared LCA-SMEDDS was characterised by transmission electron microscopy analysis, particle size, polymer dispersity index (PDI), zeta potential, stability tests and in vitro release analysis. LCA-SMEDDS and free LCA were orally administered to Sprague-Dawley rats to investigate respective bioavailability. The hyperuricaemia rat model was established to evaluate anti-hyperuricemic activity. The particle size, PDI, and zeta potential of LCA-SMEDDS were 25.68 ± 0.79 nm, 0.074 ± 0.024, −14.37 ± 2.17 mV. The oral bioavailability of LCA-SMEDDS was increased 2.36-fold compared with the free LCA. The uric acid level of LCA-SMEDDS group (200 mg/kg) was decreased 60.08% compared with model control group. The developed LCA-SMEDDS could be an outstanding candidate for improving oral bioavailability and anti-hyperuricemic activity of LCA. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF